The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 26 de julio del 2011
Friday, September 9, 2011
7:30 AM — 8:00 AM Registration and Continental Breakfast
8:00 AM — 5:00 PM Educational Session
Download Conference PDF
University of Pennsylvania Biomedical Research Building II/III
421 Curie Boulevard
Debbie L. Cohen, MD
David C. Metz, MD
This conference is designed for endocrinologists, internists, oncologists, gastroenterologists, geneticists, nephrologists, pathologists, radiologists, specialists in nuclear medicine, physician assistants, nurses, nurse practitioners and other allied health professionals.
Neuroendocrine tumors (NETs) consist of a relatively homogeneous group of tumors that are often well-differentiated and associated with an indolent clinical course. While considered to be rare, their incidence has been on the rise
(the prevalence of these tumors is quite large, >100,000 in the USA). These tumors develop from the neuroendocrine cells dispersed throughout the body and they are generally incurable in the setting of metastatic disease. Due to their ability to produce hormones, their clinical presentations can be rather dramatic and varied. Successful management requires an understanding of the disease process as a whole and a multi-modality approach with contributions from medical oncology, surgery, endocrinology, gastroenterology,
nephrology, pathology, interventional and diagnostic radiology, nuclear medicine and genetics.
This CME program has been designed to provide cutting edge information on all aspects of NET patient management.
Upon completion of the program, learners should be able to:
For more information, please see the conference PDF.English
Jul 17, 2012 - The combination of temozolomide and bevacizumab seems to benefit patients with advanced pancreatic neuroendocrine tumors, according to a study published online July 9 in the Journal of Clinical Oncology.